Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

Julio A. Gutierrez; Carmen Landaverde; Jennifer T. Wells; Fred Poordad

doi:10.1002/hep.28556

Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

Julio A. Gutierrez, Carmen Landaverde, Jennifer T. Wells, Fred Poordad

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m². Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301–302).

Original language	English (US)
Pages (from-to)	301-302
Number of pages	2
Journal	Hepatology
Volume	64
Issue number	1
DOIs	https://doi.org/10.1002/hep.28556
State	Published - Jul 1 2016

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.28556

Cite this

@article{89fa6f64d4674e0599b41749a7649703,

title = "Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient",

abstract = "Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301–302).",

author = "Gutierrez, {Julio A.} and Carmen Landaverde and Wells, {Jennifer T.} and Fred Poordad",

note = "Publisher Copyright: {\textcopyright} 2016 by the American Association for the Study of Liver Diseases",

year = "2016",

month = jul,

day = "1",

doi = "10.1002/hep.28556",

language = "English (US)",

volume = "64",

pages = "301--302",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

AU - Gutierrez, Julio A.

AU - Landaverde, Carmen

AU - Wells, Jennifer T.

AU - Poordad, Fred

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301–302).

AB - Management of obesity and decompensated cirrhosis in those requiring liver transplantation (LT) is a challenging dilemma. Because of concerns for perioperative complications, many centers avoid transplant in those with a body mass index (BMI) greater than 40 kg/m2. Bariatric surgery is associated with increased risk attributable to complications of portal hypertension, including variceal rupture. Therefore, weight loss and LT options are limited. Several new classes of weight loss drugs are commercially available, including the anoretic, lorcaserin. This case illustrates the successful use of lorcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing. (Hepatology 2016;64:301–302).

UR - http://www.scopus.com/inward/record.url?scp=84976481098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976481098&partnerID=8YFLogxK

U2 - 10.1002/hep.28556

DO - 10.1002/hep.28556

M3 - Article

C2 - 26991688

AN - SCOPUS:84976481098

SN - 0270-9139

VL - 64

SP - 301

EP - 302

JO - Hepatology

JF - Hepatology

IS - 1

ER -

Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this